Friday, 16 October 2026European Markets

SOLVAY And TITAN CEMENT Have A High Dividend Yield And Return On Equity In The Basic Materials Sector.

Loading stream...

(VIANEWS) - SOLVAY (SOLB.BR) is among this list of stock assets with the highest dividend rate and return on equity on the Basic Materials sector.

Financial Asset Price Forward Dividend Yield Return on Equity
SOLVAY (SOLB.BR) €107.60 4.65% 19.82%
TITAN CEMENT (TITC.BR) €14.92 4.07% 8%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. SOLVAY (SOLB.BR)

4.65% Forward Dividend Yield and 19.82% Return On Equity

Solvay SA provides advanced materials and specialty chemicals worldwide. It operates through four segments: Materials, Chemicals, Solutions, and Corporate & Business Services. The Materials segment offers specialty polymers, including aromatic polymers, high barrier polymers, and fluoropolymers for the electronics, automotive, aircraft, and healthcare industries; and composite materials for aerospace engineered materials market. The Chemicals segment produces and sells soda ash and sodium bicarbonate primarily to the flat and container glass industries, as well as for use in detergents, pharmaceutical, and feed and food industries; hydrogen peroxide for use primarily in the paper industry to bleach pulp, as well as chemicals, electronics, food, mining, and environment; and dispersible silica for tire manufacturers; and solvent solutions, specialty phenols, polyamide derivatives and smart, functional, and sustainable yarns and polymers. The Solutions segment offers specialty chemicals for agro, home and personal care, coatings, and industrial markets; technology solutions in specialty mining reagents, phosphine-based chemistry, and solutions for the stabilization of polymers; fluorine and rare-earth formulations for automotive, electronics, agrochemical, and construction applications; and vanillin for the flavors and fragrances industries, as well as synthetic intermediates used in pharmaceuticals, agrochemicals, and electronics. This segment also provides friction reducers, gelling agents, emulsion breakers, surfactants, inhibitors, cementing additives, and biocides for upstream oilfield chemicals sector, as well as sodium hypophosphite for metal plating and other applications. The Corporate & Business Services segment provides energy and other business services. The company was founded in 1863 and is headquartered in Brussels, Belgium.

Earnings Per Share

As for profitability, SOLVAY has a trailing twelve months EPS of €18.29.

PE Ratio

SOLVAY has a trailing twelve months price to earnings ratio of 5.88. Meaning, the purchaser of the share is investing €5.88 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.82%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SOLVAY's stock is considered to be overbought (>=80).

More news about SOLVAY.

2. TITAN CEMENT (TITC.BR)

4.07% Forward Dividend Yield and 8% Return On Equity

Titan Cement International S.A., together with its subsidiaries, produces, distributes, and trades in a range of construction materials in Greece and Western Europe, North America, Southeastern Europe, the Eastern Mediterranean, and internationally. The company provides cement; ready-mix concrete; aggregates and coarse materials, including sand, gravel, crushed stone, and recycled concrete; and other building materials, such as dry mortars, building blocks, fly ash, and other concrete products for the construction of roads, bridges, airports, hospitals, schools, residential housing, commercial buildings, and social projects. It is also involved in the import and distribution of cement; processing of fly ash; sale of fly ash processing equipment; quarries; real estate brokerage services; engineering design services for solid and liquid waste facilities; and alternative fuels. In addition, the company provides trading, technical and business, port, financial, preventing maintenance, insurance, and transportation services; owns and develops real estate properties; rents and leases machines, equipment, and material goods; and designs, manufactures, and markets proprietary separation equipment for dry powders. Titan Cement International S.A. was founded in 1902 and is based in Brussels, Belgium.

Earnings Per Share

As for profitability, TITAN CEMENT has a trailing twelve months EPS of €1.53.

PE Ratio

TITAN CEMENT has a trailing twelve months price to earnings ratio of 9.75. Meaning, the purchaser of the share is investing €9.75 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8%.

Volume

Today's last reported volume for TITAN CEMENT is 3381 which is 79.14% below its average volume of 16213.

Moving Average

TITAN CEMENT's worth is higher than its 50-day moving average of €14.72 and way above its 200-day moving average of €12.61.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Jun 28, 2023, the estimated forward annual dividend rate is 0.6 and the estimated forward annual dividend yield is 4.07%.

More news about TITAN CEMENT.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com